Omniab (OABI) Stock
Small cap healthcare company developing new medicines. Here's the price, business snapshot, and what's worth knowing about Omniab in June 2026.
OMNIAB Inc (OABI) is a small-cap company with a market capitalisation of about $203.7 million. For investors, the key points are size, liquidity and information access: small-cap stocks can offer higher growth potential but tend to be more volatile and less liquid than larger companies. Public disclosures, earnings cadence and management track record are particularly important when assessing a firm this size. Before considering OABI, review the company’s latest filings, analyst notes and newsflow to understand its business model, revenue drivers and cash position. Expect wider bid-ask spreads and potentially larger price swings on lower volumes. This summary is general, educational information only, not personal advice. Values can rise and fall and past performance is not a reliable guide. Ensure any decision aligns with your risk tolerance, timeframe and diversification strategy; consider seeking independent financial advice if you are unsure.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying OMNIAB INC's stock with a target price of $7.33, indicating strong potential growth.
Financial Health
OMNIAB INC is performing well with strong cash flow, high profit margins, and solid revenue.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring OABI
Ozempic Price Pressure | Pharma Investment Shift
A recent announcement of plans to slash prices for major weight-loss drugs has created turmoil for market leaders Novo Nordisk and Eli Lilly. This theme explores the investment opportunities that arise for competing pharmaceutical companies and developers of alternative treatments who may benefit from this market disruption.
Published: 21 October 2025
Explore BasketAI-Driven Drug Discovery
These groundbreaking companies are redefining pharmaceutical research with artificial intelligence. Each has been carefully selected by our analysts for their potential to develop life-saving drugs faster and more efficiently than traditional methods allow.
Published: 17 June 2025
Explore BasketMicrobiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small-cap dynamics
Smaller market cap can mean faster growth potential but also higher volatility; monitor position sizing and time horizon, as performance can vary.
Research essentials
Prioritise filings, earnings commentary and cash position to understand the business model and risks; third-party analysis can add useful perspective.
Liquidity & risk
Lower trading volumes may lead to wider spreads and larger price moves; consider diversification and match exposure to your risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
